psychiatryПСИХИАТРИЯPsychiatry (Moscow) (Psikhiatriya)1683-83192618-6667FSBSI “The Mental Health Research Centre”; LLC «Publisher «MIA»psychiatry-346Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSБлокада ɑ1-адренорецепторов: роль в терапии психических расстройствBlockade of Alpha-1-adrenoceptors: role in the therapy of mental disordersСюняковT. С.SyunyakovT. S.

Сюняков Тимур Сергеевич - кандидат медицинских наук.

Москва.

Syunyakov Timur - candidate of medical sciences MD.

Moscow.

sjunja@bk.ruООО «Пфайзер»РоссияPfizer LLCRussian Federation201815112018078150157Copyright © Сюняков T.С., 20182018Сюняков T.С.Syunyakov T.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.journalpsychiatry.com/jour/article/view/346Цель

Цель: представить обзор нарушений функции ɑ1-адренорецепторов (А1АР) при различных психических расстройствах с целью выявить наиболее перспективные направления клинических и экспериментальных исследований.

Результаты

Результаты: среди препаратов, связывающихся с А1АР наибольшее значение для клинического изучения приобрели их антагонисты. Основной фокус исследований вовлеченности А1АР направлен на изучение нейрокогнитивных расстройств, расстройств, связанных со стрессом и шизофрении. При данных расстройствах была продемонстрирована целесообразность и перспективность клинического изучения проникающих через гематоэнцефалический барьер (ГЭБ) антагонистов А1АР.

Вывод

Вывод: активное изучение А1АР и норадренергической функции определяет механизмы ее нарушений и перспективы терапевтического вмешательства.

Objective is to overview of the alpha-l-adrenoceptor dysfunction involvement in the various mental disorders pathogenesis and it is aimed to identify the most promising areas of clinical and pilot studies.

Results

Results: among medications interacting with alpha-l-adrenoceptors the highest significance has been demonstrated for their antagonists. Generally, studies on the role of alpha-l-adrenoceptors yielded most promising results in the fields of neurocognitive disorders, stress-related disorders and schizophrenia. In these disorders selective alpha-l-adrenoblockers penetrating through the blood-brain barrier are reasonable candidates for the clinical evaluation.

Conclusion

Conclusion: active study of alpha-l-adrenoceptors and its disfunction determine pathway mechanisms and perspectives of therapeutical intervention.

А1АРострая реакция на стресспосттравматическое стрессовое расстройство (ПТСР)нейрокогнитивные расстройствашизофренияпразозинницерголинalpha-l-adrenoblockersacute stress reactionpost-traumatic stress disorderneurocognitive disordersschizophreniaPrazosinNicergolineReferencesKozisek М.Е., Bylund D.B. Norepinephrine/epinephrine. In: Hoboken N.J. Handbook of contemporary neuropharmacology. USA: John Wiley & Sons; Inc., 2007. doi: 10.1002/9780470101001.hcn006.Kozisek M.E., Bylund D.B. Norepinephrine/epinephrine. In: Hoboken N.J. Handbook of contemporary neuropharmacology. USA: John Wiley & Sons, Inc., 2007. doi: 10.1002/9780470101001.hcn006.Arnsten A.F.T., Raskind M.A. Taylor F.B., Connor D.F. The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder. Neurobiology of Stress. 2015;l(l):89-99. doi: 10.1016/j.ynstr.2014.10.002.Arnsten A.F.T., Raskind M.A. Taylor F.B., Connor D.F. The effects of stress exposure on prefrontal cortex: Translating basic research into successful treatments for post-traumatic stress disorder. Neurobiology of Stress. 2015;l(l):89-99. doi: 10.1016/j.ynstr.2014.10.002.Yang L.J., Liu X., Liu D.X., Jiang H., Mao X.Q., Wang C., Pan F. Effects of different adrenergic blockades on the stress resistance of Wistarrats. Neurosd. Lett. 2012;511(2):95-100. doi: 10.1016/j.neulet2012.01.046.Yang L.J., Liu X., Liu D.X., Jiang H., Mao X.Q., Wang C« Pan F. Effects of different adrenergic blockades on the stress resistance of Wistar rats. Neurosci. Lett. 2012;511(2):95-100. doi: 10.1016/j.neulet2012.01.046.Arnsten A.F.T. Stress weakens prefrontal networks: molecular insults to higher cognition. Nat. Neurosci. 2015; 18(10): 1376-1385. doi: 10.1038/nn.4087.Arnsten A.F.T. Stress weakens prefrontal networks: molecular insults to higher cognition. Nat. Neurosci. 2015; 18(10): 1376-1385. doi: 10.1038/ПП.4087.Haj-Dahmane S., Shen R.-Y. Chronic stress impairs 1-adrenoceptor-induced endocannabinoid-dependent synaptic plasticity in the dorsal raphe nucleus. J. Neurosci. 2014;34(44): 14560-14570. doi: 10.1523/JNEUROSCI.1310-14.2014.Haj-Dahmane S., Shen R.-Y. Chronic Stress Impairs 1-Adrenocep- tor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus. J. Neurosd. 2014; 34(44): 14560- 14570. doi: 10.1523/JNEUROSCI.1310-14.2014.Drazinic C. et al. Neurotransmitters and Receptors in Psychiatric Disorders. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology. American Psychiatric Association Publishing, 2017. Ed. Alan F. Schatzberg Charles B. Nemeroff. doi: 10.1176/appi.books.97816153n624.as02.Drazinic C. et al. Neurotransmitters and Receptors in Psychiatric Disorders. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology. American Psychiatric Association Publishing, 2017. Ed.: Alan F. Schatzberg, Charles B. Nemeroff. doi: 10.1176/appi.books.9781615371624.as02.Knauber J., Muller W.E. Subchronic treatment with prazosin improves passive avoidance learning in aged mice: possible relationships to alpha-l-receptor up-regulation. J. Neural Transm. 2000;107(12):1413-1426. doi: 10.1007/s007020070005.Knauber J., Miiller W.E. Subchronic treatment with prazosin improves passive avoidance learning in aged mice: possible relationships to alphal-receptor up-regulation. J. Neural Transm. 2000; 107(12): 1413-1426. doi: 10.1007/s007020070005.Lee T.W., Cotecchia S., Milligan G. Upregulation of the levels of expression and function of a constitutively active mutant of the hamster alphalB-adrenoceptor by ligands that act as inverse agonists. Biochem. J. 1997;325(Pt 3): 733-739. doi: 10.1042/bj3250733Lee T.W., Cotecchia S., Milligan G. Up-regulation of thelevels of expression and function of a constitutively active mutant of the hamster alphalB-adrenoceptor byligands that act as inverse agonists. Biochem. J. 1997;325(Pt 3):733-739. doi: 10.1042/bj3250733.Stevens P.A., Bevan N., Rees S., Milligan G. Resolution of inverse agonist-induced upregulation from constitutive activity of mutants of the alpha(lb)-adrenoceptor. Mol. Pharmacol. 2000;58(2):438-448. doi: https://doi. org/10.1124/mol.58.2.438Stevens P.A., Bevan N.. Rees S., Milligan G. Resolution of inverse agonist-induced up-regulation from constitutive activity of mutants of the alpha(lb)-adrenoceptor. Mol. Pharmacol. 2000;58(2):438-448. doi: https://doi.org/10.1124/mol.58.2.438Gannon M., Che P., Chen Y., Jiao K., Roberson E.D., Wang Q. Noradrenergic dysfunction in Alzheimer's disease. Front. Neurosci. 2015;9(JUN):1-12. doi: 10.3389/fnins.2015.00220.Gannon M., Che P., Chen Y., Jiao K., Roberson E.D., Wang Q. Nor-adrenergic dysfunction in Alzheimer's disease. Front. Neurosd. 2015;9(JUN):1-12. doi: 10.3389/fnins.2015.00220.Purkayastha S., Raven P. The functional role of the alpha-1 adrenergic receptors in cerebral blood flow regulation. Indian J. Pharmacol. 2011;43(5):502. doi: 10.4103/0253-7613.84950.Purkayastha S., Raven P. The functional role of the alpha-1 adr¬energic receptors in cerebral blood flow regulation. Indian J. Pharmacol. 2011;43(5):502. doi: 10.4103/0253-7613.84950.Piascik M.T., Perez D.M. Alphal-adrenergic receptors: new insights and directions. J. Pharmacol. Exp. Ther. 2001; 298(2):403-410.Piascik M.T., Perez D.M. Alphal-adrenergic receptors: new insights and directions. J. Pharmacol. Exp. Ther. 2001;298(2):403- 410.Fitzgerald P.J. Noradrenaline transmission reducing drugs may protect against a broad range of diseases. Auton. Autacoid Pharmacol 2015;34(3-4):15-26. doi: 10.1111/aap.12019.Fitzgerald P.J. Noradrenaline transmission reducing drugs may protect against a broad range of diseases. Auton. Autacoid Pharmacol. 2015;34(3-4): 15-26. doi: 10.1111/aap.12019.Chen Z., Minneman K.P., Minneman P K.P. Recent progress in al-adrenergic receptor research Acta Pharmacol. Sin. 2005;26(11): 1281-1287. doi: 10.1111/j.l745-7254.2005.00224.x.Chen Z., Minneman K.P. Recent progress in al-adrenergic recep¬tor research Acta Pharmacol. Sin. 2005;26(11):1281—1287. doi: 10.1111/j.l745-7254.2005.00224.x.Black C.E. et al. Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001;281(4): R1097- 1104. doi: 10.1152/ajpregu.2001.281.4.R1097.Black C.E. et al. Effect of nicotine on vasoconstrictor and vasodilator responses in human skin vasculature. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001;281(4): R1097-104. doi: 10.1152/ajpregu.2001.281.4.R1097.Hock C.E., Passmore J.C. Mechanisms mediating canine renal vasoconstriction induced by nicotine infusion. Life Sci. 1985;37(21): 1997-2003. doi: 10.1016/0024-3205(85)90030-X.Hock C.E., Passmore J.C. Mechanisms mediating canine re¬nal vasoconstriction induced by nicotine infusion. Life Sci. 1985;37(21):1997-2003. doi: 10.1016/0024-3205(85)90030-X.Lecerof H. et al. Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers. J. Hypertens. Suppl. 1990;8(5):29- 33.Lecerof H. et al. Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers. J. Hypertens. Suppl. 1990;8(5):29-33.Cryer P.E., Haymond M.W., Santiago J.V., Shah S.D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N. Engl. J. Med. 1976;295(ll):573 - 577. doi: 10.1056/NEJM197609092951101.Cryer P.E., Haymond M.W., Santiago J.V., Shah S.D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N. Engl. J. Med. 1976;295(11):573—577. doi: 10.1056/NEJM197609092951101.Haase N., Herse F., Spallek B., Haase H., Morano L., Qadri F., Szijarto L.A., Rohm I., Yilmaz A., Warrington J.P., Ryan M.J., Gollasch M., Muller D.N., Dechend R., Wallukat G. Amyloid-3 peptides activate al-adrenergic cardiovascular receptors Hypertens. (Dallas, Tex. 1979). 2013;62(5):966 - 972. doi: 10.1161/HYPERTENSIONAHA.113.01348.Haase N., Herse F., Spallek B., Haase H., Morano I., Qadri F.f Szijarto I.A., Rohm I., Yilmaz A., Warrington J.P., Ryan M.J., Gollasch M., Muller D.N., Dechend R., Wallukat G. Amyloid-3 peptides activate al-adrenergic cardiovascular receptors Hy¬pertens. (Dallas, Tex. 1979). 2013;62(5):966-972. doi: 10.1161/HYPERTENSIONAHA.113.01348.Dietrich H.H., Xiang C., Han B.H., Zipfel G.J., Holtzman D.M. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol. Neurodegener. 2010;5:15. doi: 10.1186/1750-1326-5-15Dietrich H.H., Xiang C., Han B.H., Zipfel G.J., Hottzman D.M. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol. Neurodegener. 2010;5:15. doi: 10.1186/1750-1326-5-15Smith E.E., Greenberg S.M. Beta-amyloid blood vessels, and brain function. Stroke. 2009;40(7):2601-2606. doi: 10.1161/STROKEAHA.108.536839.Smith E.E., Greenberg S.M. Beta-amyloid blood vessels and brain function. Stroke. 2009;40(7):2601-2606. doi: 10.1161/STROKEAHA. 108.53 6839.Russo-Neustadt A., Cotman C.W. Adrenergic receptors in Alzheimer's disease brain: selective increases in thecerebella of aggressive patients. J. Neurosci. 1997;17(14):5573-5580. doi: https://doi.org/10.1523/JNEUROSCI.17-14-05573.1997.Russo-Neustadt A., Cotman C.W. Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients. J. Neurosci. 1997;17(14):5573 -5580. doi: https://doi.org/10.1523/JNEUROSCI.17-14-05573.1997.Antonsdottir I.M., Smith J., Kettz M., Porsteinsson A.P. Advancements in the treatment of agitation in Alzheimer's disease. Expert Opin. Pharmacother. 2015;16(11):1649-1656. doi: 10.1517/14656566.2015.1059422.Antonsdottir I.M., Smith J., Keltz M., Porsteinsson A.P. Advancements in the treatment of agitation in Alzheimer's disease, Expert Opin. Pharmacother. 2015; 16(11): 1649-1656. doi: 10.1517/14656566.2015.1059422.Peskind E.R. et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study Alzhei¬mer Dis. Assoc. Disord. 19(l):23-28. doi: 10.1097/01.wad.0000155067.16313.5e.Peskind E.R. et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study Alzheimer Dis. Assoc. Disord. 19(l):23-28. doi: 10.1097/01.wad.0000155067.16313.5e.Wang LY., Shofer J.B., Rohde K., Hart K.L., Hoff D.J., Mc- Fall Y.H., Raskind M.A., Peskind E.R. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggressioa Am. J. Geriatr. Psychiatry. 2009;17(9):744-751. doi: 10.1097/JGP.0b013e3181ab8c61.Wang L.Y., Shofer J.B., Rohde K., Hart K.L, Hoff D.J., McFall Y.H., Raskind M.A., Peskind E.R. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am. J. Geriatr. Psychiatry. 2009;17(9):744- 751. doi: 10.1097/JGP.0b013e3181ab8c61.Fioravanti M., Ricker L Nicergoline for dementia and other age associated forms of cognitive impairment In: Cochrane Database of Systematic Reviews / Ed. M. Fioravanti. Chichester, UK: John Wiley & Sons, Ltd 2001. № 4. P. CD003159. doi: 10.1002/14651858.CD003159.Fioravanti M., Flicker L. Nicergoline for dementia and other age associated forms of cognitive impairment In: Cochrane Database of Systematic Reviews / Ed. M. Fioravanti. Chichester, UK: John Wiley & Sons, Ltd 2001. N? 4. P. CD003159. doi: 10.1002/14651858.CD003159.Winblad B., Fioravanti M., Dolezal T., Logina I., Milanov I.G., Popescu D.C., Solomon A. Therapeutic use of nicergoline. Clin. Drug Investig. 2008;28(9):533-552. doi: 10.2165/00044011-200828090-00001.Winblad B., Fioravanti M„ Dolezal T., Logina I., Milanov I.G., Popescu D.C., Solomon A. Therapeutic use of nicergoline. Clin. Drug Investig. 2008;28(9):533-552. doi: 10.2165/00044011-200828090-00001.Zajdel P., Bednarski M., Sapa J., Nowak G. Ergotamine and nicergoline — facts and myths. Pharmacol. Reports. Institute of Pharmacology, Polish Academy of Sciences. 2015;67(2):360-363. doi: 10.1016/j.pharep2014.10.010.Zajdel P., Bednarski M., Sapa J., Nowak G. Ergotamine and nicergoline — facts and myths. Pharmacol. Reports. Institute of Pharmacology, Polish Academy of Sciences. 2015;67(2):360-363. doi: 10.1016/j.pharep2014.10.010.Fioravanti М„ Nakashima Т., Xu J., Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline BMJ Open. 2014;4(7):e005090. doi: 10.1136/bmjopen-2014-005090.Fioravanti M., Nakashima T., Xu J., Garg A. A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline BMJ Open. 2014;4(7):e005090. doi: 10.1136/bmjopen-2014-005090.Пономарева E.B., Телешова E.C., Сюняков T.C. Сочетание нейродегенеративных и сосудистых механизмов в патогенезе деменций позднего возраста. Психиатрия. 2017;76(4): 97-107.Пономарева E.B., Телешова E.C., Сюняков T.C. Сочетание нейродегенеративных и сосудистых механизмов в патогенезе деменций позднего возраста Психиатрия. 2017;76(4):97-107 (In Russ.)Пономарева Е.В. Применение ницерголина в геронтологической практике. Психиатрия. 2016;71(3): 106—120.Пономарева Е.В. Применение ницерголина в геронтологической практике. Психиатрия. 2016;71(3):106-120 (In Russ.)Bes A. et al. A 24-month double-blind placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur. J. NeuroL 1999;6(3):313-322. doi: 10.1046/j.l468-1331.1999.630313.x.Bes A. et al. A 24-month double-blind placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg per day in elderly hypertensive patients with leukoaraiosis. Eur. J. Neurol. 1999;6(3):313-322. doi: 10.1046/j.l468-1331.1999.630313.x.Boulu P. Effets du Sermion® surles troubles mn. esiques et les fonctions dela vie de relation. Tempo Med. 1990,397:24- 27.Boulu P. Effets du Sermion® surles troubles mn. esiques etles fonctions dela vie de relation. Tempo Med. 1990;397:24-27.Carfagna N., Cavanus S., Damiani D., Salmoiraghi P., Fariello R., Post C. Modulation of phosphoinositide turnover by chronic nicergoline in rat brain. Neurosd. Lett. 1996; 209:189-192. doi: 10.1016/0304-3940(96)12634-3.Carfagna N.. Cavanus S., Damiani D., Salmoiraghi P., Fariello R., Post C. Modulation of phosphoinositide turnover by chronic nicergoline in rat brain. Neurosd. Lett. 1996;209:189-192. doi: 10.1016/0304-3940(96)12634-3.Karczewski P. et al. Agonistic autoantibodies to the ɑ1-adrenergic receptor and the β2-adrenergic receptor in Alzheimer's and vascular dementia. Scand. J. ImmunoL 2012;75(5):524-530. doi: 10.1111/j.l365-3083.2012.02684.x.Karczewski P. et al. Agonistic autoantibodies to the al-adrenergic receptor and the 32-adrenergic receptor in Alzheimer's and vascular dementia. Scand. J. Immunol. 2012;75(5):524-530. doi: 10.1111/j.1365-3083.2012.02684.x.Zhou Z., Liao Y., Li L., Wei F., Wang B., Wei Y.f Wang M., Cheng X. Vascular damages in rats immunized by ɑ1-Adrenoceptor peptides. Cell. Mol. ImmunoL 2008;5(5):349-356. doi: 10.1038/cmi.2008.43.Zhou Z., Liao Y., Li L., Wei F., Wang B., Wei Y., Wang M., Cheng X. Vascular damages in rats immunized by al-Adrenoceptor peptides. Cell. Mol. Immunol. 2008;5(5):349-356. doi: 10.1038/cmi.2008.43.Karczewski P. et al. Antibodies to the al-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One/ed. Herholz K. 2012;7(7):e41602. doi: 10.1371/journal.pone.0041602.Karczewski P. et al. Antibodies to the al-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One / ed. Herholz K. 2012;7(7):e41602. doi: 10.1371/journal.pone.0041602.Wenzel K. et al. Potential relevance of al-adrenergic receptor autoantibodies in refractory hypertension. PLoS One. 2008;3(ll):e3742. doi: 10.1371/joumal.pone.0003742.Wenzel K. et al. Potential relevance of al-adrenergic receptor autoantibodies in refractory hypertension. PLoS One. 2008;3(ll):e3742. doi: 10.1371/journal.pone.0003742.Kung S., Espinel L, Lapid M.I. Treatment of nightmares with prazosin: A systematic review. Mayo Clinic Proceedings. 2012;87(9):890-900. doi: 10.1016/j.mayocpL2012.05.015.Kung S., Espinel Z., Lapid M.I. Treatment of nightmares with prazosin: A systematic review. Mayo Clinic Proceedings. 2012;87(9):890-900. doi: 10.1016/j.mayocp.2012.05.015.Akinsanya A., Marwaha R., Tampi R.R. Prazosin in children and adolescents with posttraumatic stress disorder who have nightmares. J. Clin. Psychopharmacol. 2017;37(1):84- 88. doi: 10.1097/JCP.0000000000000638.Akinsanya A., Marwaha R., Tampi R.R. Prazosin in children and adolescents with posttraumatic stress disorder who have nightmares. J. Clin. Psychopharmacol. 2017;37(l):84-88. doi: 10.1097/JCP.0000000000000638.Baisley S.K., Fallace K.L, Rajbhandari A.K., Bakshi V.P. Mutual independence of 5-HT(2) and al-noradrenergic receptors in mediating deficits in sensorimotor gating. Psychopharmacology (Berl). 2012;220(3):465-479. doi: 10.1007/s00213-011-2490-2.Baisley S.K., Fallace K.L., Rajbhandari A.K., Bakshi V.P. Mutual independence of 5-HT(2) and al-noradrenergic receptors in mediating deficits in sensorimotor gating. Psychopharmacology (Bert). 2012;220(3):465-479. doi: 10.1007/s00213-011-2490-2.Bakshi V.P., Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist J. Pharmacol. Exp. Ther. 1997;283(2):666-674.Bakshi V.P., Geyer M.A. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist J. Pharmacol. Exp. Ther. 1997;283(2):666-674.Alsene K.M. et aL Disruption of prepulse inhibition after stimulation of central but not peripheral alpha-1 adrenergic receptors. Neuropsychopharmacology. 2006;31(10):2150- 2161. doi: 10.1038/sj.nppi1300989.Alsene K.M. et aL Disruption of prepulse inhibition after stim-ulation of central but not peripheral alpha-1 adrenergic receptors. Neuropsychopharmacology. 2006;31(10):2150-2161. doi: 10.1038/sj.npp.1300989.Nikiforuk A. Quetiapine ameliorates stress-induced cogni¬tive inflexibility in rats. Neuropharmacology. 2013;64:357- 364. doi: 10.1016/j.neuropharm.2012.06.042.Nikiforuk A. Quetiapine ameliorates stress-induced cognitive inflexibility in rats. Neuropharmacology. 2013;64:357-364. doi: 10.1016/j.neuropharm.2012.06.042.Romon Т., Planas А.М., Adell A. Blockade of МК-801-induced heat shock protein 72/73 in rat brain by antipsychotic and monoaminergic agents targeting 02, 5-HT1A, 5-HT2A and al-adrenergic receptors. CNS Neurol. Disord. Drug Targets. 2014; 13(1): 104-111. doi: 10.2174/18715273113129990110.Romon T., Planas A.M., Adell A. Blockade of МК-801-induced heat shock protein 72/73 in rat brain by antipsychotic and monoaminergic agents targeting D2,5-HT1A, 5-HT2A and al-adrenergic receptors. CNS Neurol. Disord. Drug Targets. 2014; 13(1):104-111. doi: 10.2174/18715273113129990110.Minzenberg M.J., Yoon J.H. An index of relative central a-adrenergic receptor antagonism by antipsychotic medications. Exp. Clin. Psychopharmacol. 20H;19(l):31-39. doi: 10.1037/a0022258.Minzenberg M.J., Yoon J.H. An index of relative central a-adrenergic receptor antagonism by antipsychotic medications. Exp. Clin. Psychopharmacol. 2011;19(l):31-39. doi: 10.1037/30022258.Stahl S.M. Stahfs essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press 2013.Stahl S.M. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press 2013.

The authors declare that there are no conflicts of interest present.